Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease

Poh Lin Pauline Chan Ng; Archana Mopur; Daniel Yam Thiam Goh; Mahesh Babu Ramamurthy; Michael Teik Chung Lim; Lee Kean Lim; Pei Ling Ooi; Elizabeth Youning Ang

doi:10.1111/1756-185X.14258

Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease

Int J Rheum Dis. 2022 Feb;25(2):228-231. doi: 10.1111/1756-185X.14258. Epub 2021 Dec 9.

Authors

Poh Lin Pauline Chan Ng^{1

2}, Archana Mopur¹, Daniel Yam Thiam Goh^{1

2}, Mahesh Babu Ramamurthy^{1

2}, Michael Teik Chung Lim^{1

2}, Lee Kean Lim¹, Pei Ling Ooi¹, Elizabeth Youning Ang^{1

2}

Affiliations

¹ Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore.
² Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

PMID: 34882988
DOI: 10.1111/1756-185X.14258

Abstract

Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely to maintain remission. Serum ferritin and interleukin-18 are useful markers for tracking activity and response of JDM-associated ILD.

Keywords: clinical aspects

Publication types

Case Reports

MeSH terms

Child
Dermatomyositis / complications
Dermatomyositis / drug therapy*
Humans
Janus Kinase Inhibitors / administration & dosage*
Lung Diseases, Interstitial / diagnostic imaging
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / etiology
Lung Diseases, Interstitial / pathology
Male
Piperidines / administration & dosage*
Pyrimidines / administration & dosage*
Remission Induction / methods

Substances

Janus Kinase Inhibitors
Piperidines
Pyrimidines
tofacitinib